

Companies



Paris Biotech Santé

2020



Paris Biotech Santé

Paris Biotech Santé is an incubator and business nursery for innovative companies in the field of human health. Launched by Paris Descartes University, INSERM, ESSEC and CentraleSupélec in 2000, **Paris Biotech Santé** (PBS) is a business incubator specializing in human health.

The activity of **Paris Biotech Santé** is to select and support the development of projects of companies and innovative companies in the field of human health : new molecules, medical devices, services, connected health, artificial intelligence.

Consulting services

- Guiding startups through their process of creation and development
- Helps the startup to reinforce the team, business plan, positioning strategy, commercial approach, pre-clinical, and financing plan
- Provides startups legal and financial supports
- Provides support to the project with collective actions : organization of meetings between startups to build a dynamic and sustainable ecosystem, access to databases...

Rental space

- 900 sqm of offices and labs within the University and the Hospital Cochin with a possible access to the platforms of Cochin Institute

Your startup is growing ?

PBS manages with the RIVP, Paris Santé Cochin, a business nursery (second -step for young companies) and business hotel within Cochin hospital since 2007.

Pépinière Paris Santé Cochin is a privileged area of 5000 sqm (offices and laboratories) for Networking, R&D and clinical partnerships.

Paris Biotech Santé is a community of entrepreneurs.

This document presents the companies of the incubator, the nursery and the business hotel.



List of companies of incubator

- ▶ **Pharmaceuticals**
- ▶ **Diagnostics and biomarkers**
- ▶ **Medical Technology or scientific instrumentation**
- ▶ **E-Health / Software & Mobile Apps / Connected Places & Objects**
- ▶ **Proximity services to patients and health professionals**
- ▶ **Training dedicated to professionals**



Sector of activity

Pharmaceuticals

Team

Stéphane Thierloix
CEO
Paola Principe Nicolas
R&D Lead
Emilio Garcia Quetglas
Chief Medical Officer

Activity

AlgoTx is a biotech focussed on the topical treatment of complex pain via the repositioning of existing molecules. The ATX01 program targets Chemotherapy-Induced Peripheral Neuropathy. Clinical Development is due to start in 2020.



Contact

stephane@thierloix.com
www.algotx.com



Sector of activity

Training dedicated to professionals

Team

Frédéric Martin
CEO, Co-founder
François Jaulin
Co-founder

Activity

Medical errors are the 14th leading cause of death in the World (WHO). ASN develops tools to reduce the human and financial impact of these errors on the health system. Two main projects:

1. An anonymous and international incident reporting system using a chatbot with AI (13 newsletters published, > 60,000 downloads in 2018).
2. The SafeTeam Academy platform (serious games) focused on teamwork and non-technical skills (1st marketed: surgical checklist).



Contact

fmartin@anesthesiasafetynetwork.com
www.anesthesiasafetynetwork.com



Sector of activity

Medical Technology
or scientific instrumentation

Team

Jérémy Laurent
CEO

Activity

ASTRAVEUS offers microfluidic bio-production instruments to enable low cost, high quality, scale out of cell and gene therapies manufacturing from investigational new drug stage to post approval manufacturing of thousands of doses per year. Our instruments are based on state of the art multitask microfluidic bioreactors and allow GMP manufacturing of CGTs in a fully integrated manner with unprecedented ease and performances.



Contact

info@astraveus.com
www.astraveus.com



Sector of activity

Pharmaceuticals

Team

Thomas Joudinaud
Henri Benech
Aloise Mabondzo
Founders

Activity

Ceres Brain Therapeutics is a R&D company, spin-off from the CEA, who develops innovative treatments in rare cerebral diseases. Our first lead addresses the Creatine Transporter Deficiency, a rare genetic disorder leading to severe global and intellectual development delay. Currently in preclinical stage, we aim at starting our clinical phase I in 2021.

Contact

henri.benech@ceres-brain.com
thomas.joudinaud@ceres-brain.com
aloise.mabondzo@cea.fr



Sector of activity

Pharmaceuticals

Team

Philippe Beaune
President
Isabelle de Waziers
CSO
Marc Sapoval
Olivier Pellerin
Clinical and radiologic development

Activity

COGITH is developing a treatment for cellular hepatocarcinoma (CHC) composed of mesenchymal stem cells (MSCs) expressing a patented gene and administered intra-arterially (IA). Injection of cyclophosphamide destroys MSCs and tumor cells and leads to an anti-tumor immune response that allows the eradication of tumors, and protects against recurrence and metastasis. We currently have a mouse clone and a human clone of MSCs (patent pending, 10/2019).

Contact

cogith@gmail.com
www.cogith.fr



Sector of activity


E-Health / Software & Mobile Apps /
Connected Places & Objects

Team

François-Guïrec Champoiseau
CEO and Co-founder
Hugo Breitwiller
Cofounder, Chief Product Officer
and HR manager
Charles Parnot
Chief scientist officer
Ihcène Medjber
Chief technical officer

Activity

Cureety provides care facilities with a set of tools and services to help them improve follow-up and care of patients having cancer in real-world conditions and in clinical trials conditions.



Contact

contact@cureety.com
www.cureety.com



Sector of activity

Diagnostics and biomarkers

Team

Cesare Massart
CEO

Jean-François Rossi

Chief Medical Officer

Kalle Levon

Chief Scientific Officer

Activity

E-Sana is a breakthrough point-of-care diagnostic technology company, using ionic-charge-sensitive transistor-based on CMOS technology to deliver biological diagnostics in minutes at low cost and automated use. E-Sana, based on a BtoB model, aims to become the leading provider of Point of Care and Home Diagnostic testing by partnering with main market players.



Contact

cesare.massart@esana.fr
www.esana.fr



Sector of activity

Pharmaceuticals

Team

Jeanne Volatron
CEO

Nicolas Rousseau

COO

Julien Branchu

R&D Manager

Amanda Silva Brun

CSO

Activity

EverZom works towards the democratization of regenerative medicine, using biological subcellular tools extracellular vesicles which are considered as an efficient and safer alternative to cell therapies. EverZom, a spin off from a CNRS laboratory, has developed and patented an innovative process which enables a high yield and fast-forward production of extracellular vesicles at large scale to support researchers from the pharmaceutical industry to design breakthrough biodrugs.

Contact

jeanne.volatron@everzom.com
www.everzom.com



Sector of activity

Pharmaceuticals

Team

Benjamin Hadida
CEO & Co-founder

Activity

Exelium Biosciences is an emerging biotechnology company specialized in the research & development of new treatments derived from the human gut microbiota. Our lead drug candidate is a monoclonal microbial product with strong anti-inflammatory properties to treat Inflammatory Bowel Diseases (such as Crohn's Disease, Ulcerative Colitis, etc.).



Contact

bhadida@exeliombio.com
www.exeliombio.com



Sector of activity

Pharmaceuticals

Team

Emilie Garcin

Regulatory Affairs Director
& Qualified Person

Franck Pigache

CEO/CFO

Activity

GENNISIMUM Pharma is specialised in development, registration and commercialization of drugs in neonatology (preterm and terms infants). Its activities consists notably in repositioning some known molecules on neonates indications with suitable formulations and presentations. A first application has been submitted to EMA on October 2019 and other projects are under development.

Contact

egarcin@gennisium.com
fpigache@gennisium.com



Sector of activity

E-Health / Software & Mobile Apps /
Connected Places & Objects

Team

Valery Trosini-Desert

Founder

Serge Kinkingnehun

President

Activity

41 million inhalers are sold per year in France. 30 to 40% of patients do not know how to use their inhaler correctly, which has significant medical and economic consequences. HEPHAÏ offers a solution for verifying the proper use of inhalers prescribed in asthma and COPD through motion analysis based on artificial intelligence.

Contact

valery.trosini-desert@aphp.fr
serge@es2ka.com



Sector of activity

Pharmaceuticals

Team

Tanguy Boissenot
CEO

Alexandre Bordat

CTO

Nicolas Tsapis

Scientific Advisory

Julien Nicolas

Scientific Advisory

Activity

IMESCIA is developing a new subcutaneous injectable sustained release formulation of anticancer drugs. The technology stems from the Institut Gallien Paris Sud (CNRS / Paris-Saclay University). Our formulation is particularly interesting for highly active anticancer drugs because it will allow to control the exposure and thus improve the efficacy. Beyond this improvement our subcutaneous formulation is an easy-to-use alternative to the intravenous route.



Contact

tanguy.boissenot@imescia.com



Sector of activity

Pharmaceuticals

Team

Clément de Obaldia
CEO

Pierre-Yves Nogue
CSO

Frédéric Ros

Researcher

Paul Ahavi

Researcher

Activity

Inovactis has developed a first immuno-therapy platform against any cancer type, tested on melanoma mice with a patented technology. Inovactis expertise relies both on synthetic biology and immunology to develop a personalized treatment against cancer, with a yeast platform able to activate the patient immune system against its own tumor directly in vivo.

Contact

contact@inovactis.com
www.inovactis.com



Sector of activity

E-Health / Software & Mobile Apps /
Connected Places & Objects

Team

Bogdan Nedelcu

CEO, Founder

Thomas Gelot

Adviser

Julien Erdogan

Product Engineer

Guillermo Durand

Research Engineer AI

Charles-Emmanuel Dias

Research Engineer AI

Activity

Our new BLE IoT platform allows hospital staff to instantly find assets and patients. It automatically compiles these location data (utilization rate of materials, patient flows, processes), and create an easy-to-read KPI dashboard to assist hospital managers in decision making. Our solution optimizes flows, reduces costs, improves the patient experience and the satisfaction of hospital staff.

Contact

bogdan@intelligentlocations.io
support@intelligentlocations.io
www.intelligentlocations.io



Sector of activity

E-Health / Software & Mobile Apps /
Connected Places & Objects

Team

Pierre Delpey

CEO, Pharmacist Manager

Stéphane Augé

Communication Manager

Julien Cristofini

Financial Manager

Clément Pallière

IT Manager

Natael Sole

Medical Manager

Bertrand Duprez

Commercial Manager

Activity

Medcycle is the first startup which offers a secured web platform dedicated to the pharmaceutical products exchange between pharmacists. In a public health approach Medcycle reduces the treatment interruptions by pooling pharmacies' stocks. Medcycle also allows the optimization of inventories by the exchanges of unsold products. MedCycle is the new digital tool required for a modern practice of pharmacy in a full respect of the french Health Legislation and European Data Protection Regulation.



Contact

contact@medcycle.fr
www.medcycle.fr



Sector of activity

E-Health / Software & Mobile Apps /
Connected Places & Objects

Team

Alexandre Parpaleix

CEO & Medical Director

Thomas Gavaille

CTO, Datascientist

Malo Huard

Chief Science Officer,

Deep-Learning expert

Ronan Riochet

Deep-Learning expert

Antoine Sauvage

Front-End Developer

Romain Cazavan

Business Development

Jean Seguy

Sales & Partnerships

Activity

Milvue develops cutting-edge Deep-learning algorithms for emergency x-rays made for workflow efficiency. By automating the detection of X-Rays-related abnormalities and triaging exams for radiologists to focused first on the most critical ones, Milvue is the very first solution to enable radiologists manage more efficiently the increasing flow of radiographs, while saving medical time and preventing diagnosis errors.

Contact

contact@milvue.com
www.milvue.com



Sector of activity

E-Health / Software & Mobile Apps /
Connected Places & Objects

Team

Fanny Levy

Founder & CEO

Gilles Rautureau

Co-founder

Cédric Poigneau

Executive director

Jean Roubas

CTO

Activity

The ambition of MyReVe is to spread the expertise of virtual reality to prevent, detect and overcome the fears. We develop automatized programs with training exercises. A stress score is calculated with physiological measures recorded during the experience. The live adaptation of the virtual world according to the user's reaction is patented. Our programs are aimed at B2B.

Contact

fanny.levy@myreve.fr
www.myreve.fr



Sector of activity

E-Health / Software & Mobile Apps /
Connected Places & Objects

Team

Thomas Duval

CEO

Fajwel Fogel

CSO

Franck Charras

CTO

Activity

Our team is composed of experts in health and machine learning. We are offering to automate and optimize the coding process of hospital stays from the medical record by applying the latest technics in machine learning. Our customers, which are several private and public institutions, are reaching high-performance results.

Contact

contact@sancare.fr
www.sancare.fr



Sector of activity

Pharmaceuticals

Team

François Cavalié
CEO

Anne-Geneviève Marcelin

Founder, Virologist

Nicolas Dupin

Founder, Dermatologist

Vincent Calvez


Founder, Virologist

Philippe Grange

Founder, Biochemist

Activity

SkinDermic is specialized in the discovery of innovative products in the field of inflammatory and infectious dermatology. More specifically, we develop topical repositioned molecules that reduce the duration of development and ensure the safety of the proposed products. Two axes are developed with anti-inflammatory molecules against acne lesions and pro-apoptotic molecules against Kaposi's disease lesions.



Contact

cavaliéfrancois@gmail.com



Sector of activity

Pharmaceuticals

Team

Karine Rossignol

MSc, PharmD, Co-founder, CEO

Pr Marina Cavazzana

MD, PhD, Co-founder, CMO

Dr Isabelle André

PhD, Co-founder, CSO

Activity

Smart Immune is a biopharmaceutical company in clinical stage, developing an innovative automated ex-vivo thymus technology. It will be used to produce immunology biotherapies capitalizing on T cell compartment. Dr André and Pr Cavazzana, 2 worldwide pioneers in cell and gene therapy have created this ex-vivo artificial thymus which replicates in one week the natural T Cells differentiation process compared to over 12 months in humans.



Contact

karine.rossignol@smart-immune.com



Sector of activity

Pharmaceuticals

Team

Christian Brechot
CEO

Paul Amouyal

Director

Gilles Amouyal

Director

Laure Jamot

COO/CSO

Christophe Magnan

Founder

Aurélien Le Lay

Engineer R&D

Erwann Philippe

Technician R&D

Activity

THAC is developing a drug candidate for healthy aging by treating insulin resistance that is a key actor of age-related diseases. The proof of concept and of efficacy will be performed in Type 2 diabetic patients as a first indication.

Contact

contact@thac.fr



Sector of activity

E-Health / Software & Mobile Apps /
Connected Places & Objects

Team

Hassan Lahlou

Co-founder

Ali Azad

Co-founder

Activity

UBIQUE is a fun solution that accompanies children and adults with disabilities in their motor rehabilitation. With UBIQUE Kids, children can perform their motor rehabilitation exercises while playing video games, thanks to motion sensors and a mobile application.



Contact

hassan@ubique.tech
www.ubique.tech



Sector of activity

Medical Technology
or scientific instrumentation

Team

Vincent Duboc


CEO - Logistics

Rémy Duboc

CTO - Physiotherapy

Activity

A third of work-related injuries are linked to manual handling at the workplace. Ximo develops a flexible and motorless exoskeleton to ease manual load handling. Ximo prepares for the future of work, reducing daily fatigue and body wear and tear.



Contact

vincent@ximo.fr
www.ximo.fr



List of companies of business nursery

- ▶ Pharmaceuticals
- ▶ Diagnostics and biomarkers
- ▶ Medical Technology or scientific instrumentation
- ▶ E-Health / Software & Mobile Apps / Connected Places & Objects
- ▶ Proximity services to patients and health professionals
- ▶ Training dedicated to professionals

Sector of activity


Pharmaceuticals

Team

Dr. Gilles Avenard
CEO

Activity

Acticor Biotech is a biotechnology company, a spin-off of INSERM. The company is developing ACT017, an innovative first-in-class drug candidate for the emergency treatment of thrombotic diseases such as ischemic stroke or pulmonary embolism. The drug candidate is currently in clinical study.



Contact

contact@acticor-biotech.com
www.acticor-biotech.com

Sector of activity

Medical Technology
or scientific instrumentation

Team

Petr Jaros
CEO
Gabriel Sirat
CSO

Activity

BioAxiAl designs and manufactures super resolution modules for the life sciences under the name of CODIM. Our technology, 100% French, is based on conical diffraction. Our innovative and easy-to-use solutions make it possible to obtain super-resolved microscopy images, fixed and live, without special sample preparation. BioAxiAl is the winner of the SME instruments 2018, as part of the H2020 project.

Sector of activity

Medical Technology
or scientific instrumentation

Team

Benjamin Bertrand
CEO
René Spaargaren
Chief Medical Officer
Luc Morriset
Quality & Regulatory Affairs
Director
Fabienne Betting
Chief Technical Officer

Activity

Cardiawave is a clinical stage company which develops a non-invasive ultrasound therapy device to treat Calcific Aortic Stenosis, a life threatening disease which affects 5 million people in Europe.



Contact

Véronique Asty Office Manager :
contact@cardiawave.com
www.cardiawave.com

Sector of activity

E-Health / Software & Mobile Apps /
Connected Places & Objects

Team

Prune Nercy
Catherine Franc
Pauline d'Orgeval

Activity

Deuxiemeavis.fr is an innovative and unique service in France providing patients and their loved ones with the opportunity to seek a second medical opinion in case of severe conditions, within 7 days, from physicians who have a very high level of expertise in their illness.



Contact

pauline.dorgeval@deuxiemeavis.fr
Tel. 06 84 99 91 73
www.deuxiemeavis.fr

Sector of activity

Pharmaceuticals

Team

Xavier Duportet
Chief Executive Officer
David Bikard
Chief Scientific Officer
Aurélien Grienberger
Chief Business Officer

Activity

Eligo Bioscience is a preclinical stage synthetic biology startup that is developing a platform of precise biotherapies for the microbiome. We develop Eligobiotics, biological nanorobots made up of proteins and synthetic DNA, which make it possible to deliver specific therapeutic payloads in the microbiome. On this day, Eligo raised \$ 24M and was recognized by the World Economic Forum as one of the 30 most innovative companies in the world.



Contact

contact@eligo-bioscience.com
www.eligo-bioscience.com

Sector of activity


Diagnostics and biomarkers

Team

Cécile Real
CEO
Karine Mignon Godefroy
VP Head of R&D
Arnaud Beurdeley
Scientific Director
Hélène Beny
Laboratory Director

Activity

Endometriosis is a complex disease that affects 10% of women of child-bearing age (180 million women worldwide) and negatively impacts their quality of life (pain, bleeding, infertility, chronic fatigue...). Endodiag develops innovative products and services to provide healthcare professionals with new solutions to diagnose earlier and more easily this disease while improving patient management.



Contact

contact@endodiag.com
www.endodiag.com



Sector of activity

Pharmaceuticals

Team

Naseem Amin

Chief Executive Officer

Alain Huriez

Chairman of the Board of Directors
Global Head of Regulatory Affairs and Compliance

Nolwenn Le Rhun

General Manager Gmpo France SAS

Audrey Henry

Medical Director France

Monique Arras

General Executive Assistant & Office Manager

Magali Parin

Executive Assistant Gmpo France SAS

Activity

Our mission is to identify and develop innovative therapies in the field of rare diseases (more than 7000 known). We have a network of global experts and work with scientists, academic institutions and companies with technologies and products to enable their development and commercialization. Gmp-Orphan (GMPO) was founded in 2011 and its most advanced product is Cuprior for the treatment of Wilson's disease that affects 1 in 30,000 people.

Contact

naseem@gmp-o.com
monique@gmp-o.com / info@gmp-o.com
www.gmp-o.com / www.cuprior.com



Sector of activity

Pharmaceuticals

Team

Christine Placet

CEO

Jean-Yves Deslandes

CMO

Philippe Moullier

CSO

Jérôme Vailland

CFO

Nicole Brument

CMC

Séverine Marconi

Regulatory affairs

Anne Galy

Projects manager

Gaelle Lefevre


Project manager

Magaly Leveque

Office manager

Activity

Horama is a clinical-stage biopharmaceutical company developing gene therapy therapies based on vectors derived from a recombinant adeno-associated virus (rAAV) targeting rare diseases of the retina. A first phase I/II clinical trial for HORA-PDE6B was launched in November 2017 and several patients have been recruited.



Contact

c.placet@horama.fr
www.horama.fr



Sector of activity

Medical Technology
or scientific instrumentation

Team

Julien Autebert


CEO

Amel Bendali

COO

Activity

Inorevia is a spin-off from Institut Curie/CNRS (Paris) leveraging over 10 years of research in microfluidics to tackle challenges of modern Biology and Medicine with faster, cheaper, miniaturised sample preparation. Inorevia's ground-breaking biology platform, the MAGELIA, will provide Biologists and Clinicians with a unique tool to efficiently process raw biological samples upstream of advanced analysis methods in volumes 100 to 1000 times smaller, in an entirely automated platform.



Contact

julien.autebert@inorevia.com



Sector of activity

Proximity services to patients
and health professionals

Team

Jean-François Dhainaut

CEO

Guillaume Galiay

Deputy Director

Maud Saporta

Medical Affairs Director

Edouard de Saint-Exupery

Project Manager

Sylviane Baudonnel

Office manager

Eugénie Hua

Multimedia Project Manager

Activity

Non-profit foundation, created in 2016 by the Regional Health Agency, the Lab Santé supports the promotion, acceleration and dissemination of health innovations. Federated around the same issues of public health and efficiency, our network engages in experimentation, evaluation and dissemination of innovations most useful to the health system. Grouped around a multidisciplinary team and expert Lab Santé is able to address all players in the health system.

Contact

s.baudonnel@labsante-idf.fr
www.labsante-idf.fr



Sector of activity

Diagnostics and biomarkers

Team

Dr Nathalie Ledee

CEO

Marie Petitbarat

Executive Director

Katia Vezmar

Engineer

Lucie Chevrier

Engineer

Activity

MatriceLab Innove is an innovation laboratory in reproductive medicine that explores the uterine immunological mechanisms at the origin of unexplained embryo implantation failures. Our approach is diagnostic – based and allows, when disequilibrium in local immune is detected, to provide customized solutions in order to restore the endometrial equilibrium and thus improve the embryo implantation. Our clinical goal is to double the average birth rates after IVF.

Contact

matricelab@gmail.com
Tel. 06 41 67 46 25
www.matricelabinnove.com



Sector of activity

E-Health / Software & Mobile Apps /
Connected Places & Objects

Team

David Sainati

CEO

Gilles Braud

Associate director

Activity

Medappcare is the first european certification body to be accredited in the mobile health sector (COFRAC accreditation n°5-0598, www.cofrac.fr). Medappcare assesses and certifies mobile health apps and websites in the areas of healthcare, disabilities, autonomy loss and animal health. It also offers training for healthcare professionals and companies about issues in the mobile health sector.



Contact

d.sainati@medappcare.com
Tel. 06 81 57 45 13
www.medappcare.com



Sector of activity

Diagnostics and biomarkers

Team

Yamina Ghomchi

CEO

Laurent Boitard

COO

Activity

MilliDrop develops Life Science automation solutions. Thousands of µl size reactors are automatically created, incubated and analyzed inside a benchtop instrument. MilliDrop's first product targets microbiology laboratories in need of cost effective and high throughput culture and analysis solutions.

MilliDrop is developing an IVD product to diagnose infectious diseases. It will isolate pathogens from patients' samples and determine Minimum Inhibitory Concentration in less than 24 hours.



Contact

contact@millidrop.com
www.millidrop.com



Sector of activity

Medical Technology
or scientific instrumentation

Team

Nikos Paragios


President & CTO

Catherine Martineau-Huynh

COO

Activity

Therapanacea is a medical technology company founded in 2017 as a spin-off from research laboratories of CentraleSupélec, one of the major French Institute of Technology. TheraPanacea develops intelligent softwares for diagnosis, prognosis and treatment in the oncology sphere. Their first product ART-Plan is a software suite for planning, execution and monitoring of radiotherapy treatments that achieves personalized and adaptive radiotherapy.



Contact

contact@therapanacea.eu
www.therapanacea.eu



Sector of activity

E-Health / Software & Mobile Apps /
Connected Places & Objects

Team

Matthieu Leclerc-Chalvet

CEO

Pierre Fillard

Founder, CSO

Activity

Set up in 2013 by Olivier Clatz and Pierre Fillard, Therapixel has emerged as one of the leading startups specializing in artificial intelligence applied to medical imaging. In 2017, the company won the Digital Mammography Dream Challenge. Since then, Therapixel has kept improving its breast cancer screening algorithm to reach the level of performance of the best radiologists. The alliance of a passionate team and a high-performance technology allows Therapixel to push the limits of medical imaging.



Contact

contact@therapixel.com
www.therapixel.com



List of companies of business hotel

- ▶ Pharmaceuticals
- ▶ Diagnostics and biomarkers
- ▶ Medical Technology or scientific instrumentation
- ▶ E-Health / Software & Mobile Apps / Connected Places & Objects
- ▶ Proximity services to patients and health professionals
- ▶ Training dedicated to professionals



Sector of activity

Pharmaceuticals

Team

Fred Dom
Director HiFiBio France
Nicola Beltraminelli
Vice President, Drug Science
Annabelle Gérard
Senior Director,
External Innovation Partnership
Stephanie Beq
Senior Director Translational
Science

Activity

HiFiBio Therapeutics, is an emerging multinational in the field of biotherapies using the human immune system to fight cancers and autoimmune diseases. Thanks to our single-cell, high-throughput screening technology and biological expertise, we have the ability to accelerate the discovery and development of therapeutic antibodies, through innovative industrial and academic collaborations, to make them accessible to patients.



Contact

s.demoulin@hifibio.com
www.hifibio.com



Sector of activity

Medical Technology
or scientific instrumentation

Team

Géraldine Decaux
CEO & Founder
Jean-Alexis Grimaud
Scientific Director
Harold Baseden
Business Director
Cyprien Guernonprez
R&D Manager
Sébastien Laval
Product Manager
Emilie Osborne
Communication & Marketing
Manager
Marion Garbay
Digital Manager

Activity

InDerm develops home use devices for dermatologic and cosmetic applications. InDerm technology combines visible and infra-red light with active ingredients to improve skin treatment. InDerm technology doubles skin repair capacities. A broad range of applications are expected from skin rejuvenation to wound healing.



Contact

blandine.dorgeval@officeo.fr
www.lightinderm.com



Sector of activity

Diagnostics and biomarkers

Team

Bertrand Le Conte de Poly
CEO
Claude Boccaro
Chief Scientific Officer
François Grammont
Design & Production Manager
Alban Mounier
Software Development Manager
Emilie Benoit
Product Development Manager
Diana Mandache
R&D Project Manager

Activity

From a fresh biopsy, the LLTech Biopsy Scanner provides the image of its micro-architecture and cellular contents. This optical imaging device allows the radiologists and surgeons assess in real time the quality of the biopsy and analyze the cellular components of the resection among cancer, immune and normal cells with more than 96% accuracy (peer-reviewed published papers). Used as an intraoperative tool in the surgery room or radiology suite, the LLTech Biopsy Scanner helps clinicians improve their procedure at the patient's bed. LLTech is the only company which creates unique data and uses AI to identify cell activity and cell types in real time.

Contact

contact@lltech.fr
www.lltechimaging.com



Sector of activity

Diagnostics and biomarkers

Team

Vincent Petit
Co-founder & CEO
Luc d'Auriol
Co-founder & Chairman
Romain Kaspereit
General Manager & CFO

Activity

Metafora is developing a technology able to decipher how cells use key nutrients to fuel their metabolism. We are developing a unique, powerful platform able to detect and characterize single cell energetics to establish a timely and precise diagnosis, and actionable therapeutic monitoring. Our first CE-IV test is entering on the market to early diagnose a treatable neuro-metabolic disorder in children, and promising R&D projects are ongoing in oncology.



Contact

contact@metafora-biosystems.com
www.metafora-biosystems.com



Sector of activity


Pharmaceuticals

Team

René Azoulai
CEO
Pr. Jean-François Zagury
Founder
Hervé Do
CFO
Jean-Pierre Salles
CSO

Activity

Peptinov develops an innovative therapeutic strategy, active immunotherapy targeting self-proteins, and uses a platform which can lead to the rapid identification of immunogenic peptide candidates. The induction of anti-IL-6 or anti-IL-1 antibodies in mice and monkeys was demonstrated following treatment with Peptinov's immunotherapies. Products targeting other proteins are in development in Peptinov's R&D pipeline. Peptinov's anti-IL-6 product was successfully evaluated in an animal toxicology study and is ready for clinical development.



Contact

contact@peptinov.fr
www.peptinov.fr

FOUNDING MEMBERS :



WITH THE SUPPORT OF :



BOXINNOV SANTÉ : ce projet est co-financé par le FEDER (Fonds Européen de Développement Régional)



Paris Biotech Santé

Faculté de Médecine Paris Descartes
24, rue du Faubourg Saint-Jacques
75014 Paris

@ contact@parisbiotechsante.org

www.parisbiotechsante.org
www.boxinnov.parisbiotechsante.org

@ParisBiotech

KEY FIGURES

incubator 2000-2018



72 M€
public funds



105
Active
companies



156
projects



411
patents



148
created
companies



2314
jobs



331 M€
raised funds



502 M€
financial valuation

survival rate

93% up to 3 years

85% up to 5 years

65% up to 10 years

business nursery 2007-2018



137 M€
public funds



40
active
companies



1028
patents



44
hosted
companies



1224
jobs



963 M€
raised funds



1292 M€
financial valuation

survival rate

100% up to 3 years

97% up to 5 years

79% up to 10 years

OSE IMMUNOTHERAPEUTICS
THERACLION
DBV TECHNOLOGIES
GENOMIC VISION
PHARNEXT

